Caspase inhibitors: a review of recently patented compounds (2013-2015)

References

• Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med. 2005;258: 479–517.
   PubMed Web of Science ®Google Scholar
• Pistritto G, Trisciuoglio D, Ceci C, et al. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 2016;8:603–619.
   PubMedGoogle Scholar
• Kiraz Y, Adan A, Kartal Yandim M, et al. Major apoptotic mechanisms and genes involved in apoptosis. Tumour Biol. 2016;37(7):8471–8486.
   PubMed Web of Science ®Google Scholar
• Philchenkov AA. Caspases as regulators of apoptosis and other cell functions. Biochemistry (Mosc). 2003;68: 365–376.
   PubMed Web of Science ®Google Scholar
• Chowdhury I, Tharakan B, Bhat GK. Caspases - an update. Comp Biochem Physiol B Biochem Mol Biol. 2008;151: 10–27.
   PubMed Web of Science ®Google Scholar
• Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770–776.
   PubMed Web of Science ®Google Scholar
• Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305:626–629.
   PubMed Web of Science ®Google Scholar
• Zlender V. Apoptosis–programmed cell death. Arh Hig Rada Toksikol. 2003;54:267–274.
   PubMedGoogle Scholar
• Budihardjo I, Oliver H, Lutter M, et al. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269–290.
   PubMed Web of Science ®Google Scholar
• Enari M, Sakahira H, Yokoyama H, et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998;391:43–50.
   PubMed Web of Science ®Google Scholar
• Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res. 2000;256: 58–66.
   PubMed Web of Science ®Google Scholar
• Darding M, Meier P. IAPs: guardians of RIPK1. Cell Death Differ. 2012;19:58–66.
   PubMed Web of Science ®Google Scholar
• Silke J, Meier P. Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. Cold Spring Harb Perspect Biol. 2013;5(2):a008730.
   PubMed Web of Science ®Google Scholar
• Roy S, Nicholson DW. Cross-talk in cell death signaling. J Exp Med. 2000;192:F21–5.
   PubMed Web of Science ®Google Scholar
• Feoktistova M, Leverkus M. Programmed necrosis and necroptosis signalling. Febs J. 2015;282:19–31.
   PubMed Web of Science ®Google Scholar
• Murphy JM, Vince JE. Post-translational control of RIPK3 and MLKL mediated necroptotic cell death. F1000Res. 2015;4 ( F1000 Faculty Rev-1297) (doi: 10.12688/f1000research.7046.1).
   PubMedGoogle Scholar
• de Almagro MC, Vucic D. Necroptosis: pathway diversity and characteristics. Semin Cell Dev Biol. 2015;39:56–62.
   PubMed Web of Science ®Google Scholar
• Thompson R, Shah RB, Liu PH, et al. An inhibitor of PIDDosome formation. Mol Cell. 2015;58:767–779.
   PubMed Web of Science ®Google Scholar
• Cho K, Cho MH, Seo JH, et al. Calpain-mediated cleavage of DARPP-32 in Alzheimer’s disease. Aging Cell. 2015;14:878–886.
   PubMed Web of Science ®Google Scholar
• Harwood SM, Yaqoob MM, Allen DA. Caspase and calpain function in cell death: bridging the gap between apoptosis and necrosis. Ann Clin Biochem. 2005;42:415–431.
   PubMed Web of Science ®Google Scholar
• McCollum AT, Nasr P, Estus S. Calpain activates caspase-3 during UV-induced neuronal death but only calpain is necessary for death. J Neurochem. 2002;82:1208–1220.
   PubMed Web of Science ®Google Scholar
• Broecker-Preuss M, Muller S, Britten M, et al. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. BMC Cancer. 2015;15:184.
   PubMed Web of Science ®Google Scholar
• Lee JH, Khor TO, Shu L, et al. Dietary phytochemicals and cancer prevention: nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression. Pharmacol Ther. 2013;137:153–171.
   PubMed Web of Science ®Google Scholar
• Suboj P, Babykutty S, Srinivas P, et al. Aloe emodin induces G2/M cell cycle arrest and apoptosis via activation of caspase-6 in human colon cancer cells. Pharmacology. 2012;89:91–98.
   PubMed Web of Science ®Google Scholar
• Wen X, Lin ZQ, Liu B, et al. Caspase-mediated programmed cell death pathways as potential therapeutic targets in cancer. Cell Prolif. 2012;45:217–224.
   PubMed Web of Science ®Google Scholar
• Chauvier D, Ankri S, Charriaut-Marlangue C, et al. Broad-spectrum caspase inhibitors: from myth to reality? Cell Death Differ. 2007;14:387–391.
   PubMed Web of Science ®Google Scholar
• Ekert PG, Silke J, Vaux DL. Caspase inhibitors. Cell Death Differ. 1999;6: 1081–1086.
   PubMed Web of Science ®Google Scholar
• Fauvel H, Marchetti P, Chopin C, et al. Differential effects of caspase inhibitors on endotoxin-induced myocardial dysfunction and heart apoptosis. Am J Physiol Heart Circ Physiol. 2001;280:H1608–14,
   PubMed Web of Science ®Google Scholar
• van Noorden CJ. The history of Z-VAD-FMK, a tool for understanding the significance of caspase inhibition. Acta Histochem. 2001;103: 241–251.
   PubMed Web of Science ®Google Scholar
• Kim KW, Moretti L, Lu B. M867, a novel selective inhibitor of caspase-3 enhances cell death and extends tumor growth delay in irradiated lung cancer models. Plos One. 2008;3(5): e2275. *
   PubMed Web of Science ®Google Scholar
• Oberholzer C, Tschoeke SK, Moldawer LL, et al. Local thymic caspase-9 inhibition improves survival during polymicrobial sepsis in mice. J Mol Med (Berl). 2006;84:389–395.
   PubMed Web of Science ®Google Scholar
• Witek RP, Stone WC, Karaca FG, et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology. 2009;50:1421–1430.
   PubMed Web of Science ®Google Scholar
• Medina EA, Afsari RR, Ravid T, et al. Tumor necrosis factor-{alpha} decreases Akt protein levels in 3T3-L1 adipocytes via the caspase-dependent ubiquitination of Akt. Endocrinology. 2005;146:2726–2735.
   PubMed Web of Science ®Google Scholar
• Baskin-Bey ES, Washburn K, Feng S, et al. Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant. 2007;7:218–225.
   PubMed Web of Science ®Google Scholar
• McCall MD, Maciver AM, Kin T, et al. Caspase inhibitor IDN6556 facilitates marginal mass islet engraftment in a porcine islet autotransplant model. Transplantation. 2012;94:30–35.
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Schiff ER, Shiffman ML, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology. 2007;46:324–329.
   PubMed Web of Science ®Google Scholar
• Valentino KL, Gutierrez M, Sanchez R, et al. First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int J Clin Pharmacol Ther. 2003;41:441–449.
   PubMed Web of Science ®Google Scholar
• Poordad FF. IDN-6556 Idun Pharmaceuticals Inc. Curr Opin Investig Drugs. 2004;5:1198–1204.
   PubMedGoogle Scholar
• Cai SX, Guan L, Jia S, et al. Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: SAR of the N-protecting group. Bioorg Med Chem Lett. 2004;14:5295–5300.
   PubMed Web of Science ®Google Scholar
• Frydrych I, Mlejnek P, Dolezel P, et al. The broad-spectrum caspase inhibitor Boc-Asp-CMK induces cell death in human leukaemia cells. Toxicol In Vitro. 2008;22:1356–1360.
   PubMed Web of Science ®Google Scholar
• De Moissac D, Gurevich RM, Zheng H, et al. Caspase activation and mitochondrial cytochrome C release during hypoxia-mediated apoptosis of adult ventricular myocytes. J Mol Cell Cardiol. 2000;32:53–63.
   PubMed Web of Science ®Google Scholar
• Balsam LB, Kofidis T, Robbins RC. Caspase-3 inhibition preserves myocardial geometry and long-term function after infarction. J Surg Res. 2005;124:194–200.
   PubMed Web of Science ®Google Scholar
• Castro MM, Fuah J, Ali M, et al. Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase-2. Biochem Pharmacol. 2013;86:469–475.
   PubMed Web of Science ®Google Scholar
• Chapman JG, Magee WP, Stukenbrok HA, et al. A novel nonpeptidic caspase-3/7 inhibitor, (S)-(+)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin reduces myocardial ischemic injury. Eur J Pharmacol. 2002;456:59–68.
   PubMed Web of Science ®Google Scholar
• Han BS, Hong HS, Choi WS, et al. Caspase-dependent and -independent cell death pathways in primary cultures of mesencephalic dopaminergic neurons after neurotoxin treatment. J Neurosci. 2003;23:5069–5078.
   PubMed Web of Science ®Google Scholar
• Kuladip JBB, Pravat KP. Caspases: a potential therapeutic targets in the treatment of Alzheimer’s disease. Transl Med. 2013;S2: S2–006.
   Google Scholar
• Rutherford NJ, Zhang YJ, Baker M, et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008;4:e1000193.
   PubMed Web of Science ®Google Scholar
• Yang L, Sugama S, Mischak RP, et al. A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. Neurobiol Dis. 2004;17:250–259.
   PubMed Web of Science ®Google Scholar
• Toulmond S, Tang K, Bureau Y, et al. Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington’s disease. Br J Pharmacol. 2004;141:689–697.
   PubMed Web of Science ®Google Scholar
• Hui L, Frederick C, Ping S, et al. Caspase inhibitors reduce neuronal injury after focal but not global cerebral ischemia in rats. Stroke. 2000;31:176–182.
   PubMedGoogle Scholar
• Braun JS, Prass K, Dirnagl U, et al. Protection from brain damage and bacterial infection in murine stroke by the novel caspase-inhibitor Q-VD-OPH. Exp Neurol. 2007;206:183–191.
   PubMed Web of Science ®Google Scholar
• Han W, Sun Y, Wang X, et al. Delayed, long-term administration of the caspase inhibitor Q-VD-OPh reduced brain injury induced by neonatal hypoxia-ischemia. Dev Neurosci. 2014;36:64–72.
   PubMed Web of Science ®Google Scholar
• Renolleau S, Fau S, Goyenvalle C, et al. Specific caspase inhibitor Q-VD-OPh prevents neonatal stroke in P7 rat: a role for gender. J Neurochem. 2007;100:1062–1071.
   PubMed Web of Science ®Google Scholar
• Akdemir O, Berksoy I, Karaoglan A, et al. Therapeutic efficacy of Ac-DMQD-CHO, a caspase 3 inhibitor, for rat spinal cord injury. J Clin Neurosci. 2008;15:672–678.
   PubMed Web of Science ®Google Scholar
• Colak A, Karaoglan A, Barut S, et al. Neuroprotection and functional recovery after application of the caspase-9 inhibitor z-LEHD-fmk in a rat model of traumatic spinal cord injury. J Neurosurg Spine. 2005;2:327–334.
   PubMed Web of Science ®Google Scholar
• Colak A, Antar V, Karaoglan A, et al. Q-VD-OPh, a pancaspase inhibitor, reduces trauma-induced apoptosis and improves the recovery of hind-limb function in rats after spinal cord injury. Neurocirugia (Astur). 2009;20:533–540, discussion 540
   PubMed Web of Science ®Google Scholar
• Favaloro B, Allocati N, Graziano V, et al. Role of apoptosis in disease. Aging (Albany NY). 2012;4:330–349.
   PubMedGoogle Scholar
• Kudelova J, Fleischmannova J, Adamova E, et al. Pharmacological caspase inhibitors: research towards therapeutic perspectives. J Physiol Pharmacol. 2015;66:473–482.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Sheikh MY, Sanyal AJ, et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology. 2012;55:419–428.
   PubMed Web of Science ®Google Scholar
• Callus BA, Vaux DL. Caspase inhibitors: viral, cellular and chemical. Cell Death Differ. 2007;14: 73–78.
   PubMed Web of Science ®Google Scholar
• St-Louis MC, Massie B, Archambault D. The bovine viral diarrhea virus (BVDV) NS3 protein, when expressed alone in mammalian cells, induces apoptosis which correlates with caspase-8 and caspase-9 activation. Vet Res. 2005;36:213–227.
   PubMed Web of Science ®Google Scholar
• Brumatti G, Ma C, Lalaoui N, et al. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. Sci Transl Med. 2016;8:339ra69.
   PubMed Web of Science ®Google Scholar
• Limpachayaporn P, Schafers M, Haufe G. Isatin sulfonamides: potent caspases-3 and −7 inhibitors, and promising PET and SPECT radiotracers for apoptosis imaging. Future Med Chem. 2015;7(9):1173–1196.
   PubMed Web of Science ®Google Scholar
• Diomede L, Romeo M, Cagnotto A, et al. The new beta amyloid-derived peptide Abeta1-6A2V-TAT(D) prevents Abeta oligomer formation and protects transgenic C. Elegans Abeta Toxicity Neurobiol Dis. 2016;88:75–84.
   PubMed Web of Science ®Google Scholar
• Vandenabeele P, Vanden Berghe T, Festjens N. Caspase inhibitors promote alternative cell death pathways. Sci STKE. 2006;2006:pe44.
   PubMedGoogle Scholar
• Caserta TM, Smith AN, Gultice AD, et al. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis. 2003;8:345–352.
   PubMed Web of Science ®Google Scholar
• Choi Y, Kim HS, Shin KY, et al. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer’s disease models. Neuropsychopharmacology. 2007;32:2393–2404.
   PubMed Web of Science ®Google Scholar
• Barchet TM, Amiji MM. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opin Drug Deliv. 2009;6:211–225.
   PubMed Web of Science ®Google Scholar
• Denora N, Trapani A, Laquintana V, et al. Recent advances in medicinal chemistry and pharmaceutical technology–strategies for drug delivery to the brain. Curr Top Med Chem. 2009;9:182–196.
   PubMed Web of Science ®Google Scholar
• Mignani S, El Kazzouli S, Bousmina M, et al. Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview. Adv Drug Deliv Rev. 2013;65:1316–1330.
   PubMed Web of Science ®Google Scholar
• Spuch C, Navarro C. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer’s disease and Parkinson’s disease). J Drug Deliv. 2011;2011:469679.
   PubMedGoogle Scholar
• Hacker HG, Sisay MT, Gutschow M. Allosteric modulation of caspases. Pharmacol Ther. 2011;132:180–195.
   PubMed Web of Science ®Google Scholar
• Walters J, Schipper JL, Swartz P, et al. Allosteric modulation of caspase 3 through mutagenesis. Biosci Rep. 2012;32:401–411.
   PubMed Web of Science ®Google Scholar
• Ang MJ, Lau QY, Ng FM, et al. Peptidomimetic ethyl propenoate covalent inhibitors of the enterovirus 71 3C protease: a P2-P4 study. J Enzyme Inhib Med Chem. 2016;31:332–339.
   PubMed Web of Science ®Google Scholar
• Denes A, Lopez-Castejon G, Brough D. Caspase-1: is IL-1 just the tip of the ICEberg? Cell Death Dis. 2012;3:e338.
   PubMed Web of Science ®Google Scholar
• Qiao J, Wu J, Li Y, et al. Blockage of caspase-1 activation ameliorates bone marrow inflammation in mice after hematopoietic stem cell transplantation. Clin Immunol. 2016;162:84–90.
   PubMed Web of Science ®Google Scholar
• Rojas V, Camus-Guerra H, Guzman F, et al. Pro-inflammatory caspase-1 activation during the immune response in cells from rainbow trout Oncorhynchus mykiss (Walbaum 1792) challenged with pathogen-associated molecular patterns. J Fish Dis. 2015;38:993–1003.
   PubMed Web of Science ®Google Scholar
• Bonefeld CM, Geisler C Treatment of contact dermatitis PCT/DK2015/050068. 2015.
   Google Scholar
• Bouchier-Hayes L, Green DR. Caspase-2: the orphan caspase. Cell Death Differ. 2012;19(1):51–57.
   PubMed Web of Science ®Google Scholar
• Fava LL, Bock FJ, Geley S, et al. Caspase-2 at a glance. J Cell Sci. 2012;125(Pt 24):5911–5915.
   PubMed Web of Science ®Google Scholar
• Hu HI, Chang HH, Sun DS. Differential regulation of caspase-2 in MPP(+)-induced apoptosis in primary cortical neurons. Exp Cell Res. 2015;332(1):60–66.
   PubMed Web of Science ®Google Scholar
• Troy CM, Rabacchi SA, Friedman WJ, et al. Caspase-2 mediates neuronal cell death induced by beta-amyloid. J Neurosci. 2000;20(4):1386–1392.
   PubMed Web of Science ®Google Scholar
• Peptide TC Inhibitors of Caspase 2 Activation. US20150148302 A1. 2015.
   Google Scholar
• Engidawork E, Gulesserian T, Seidl R, et al. Expression of apoptosis related proteins in brains of patients with Alzheimer’s disease. Neurosci Lett. 2001;303:79–82.
   PubMed Web of Science ®Google Scholar
• Vigneswara V, Berry M, Logan A, et al. Pharmacological inhibition of caspase-2 protects axotomised retinal ganglion cells from apoptosis in adult rats. PLoS One. 2012;7:e53473.
   PubMed Web of Science ®Google Scholar
• Pozueta J, Lefort R, Ribe EM, et al. Caspase-2 is required for dendritic spine and behavioural alterations in J20 APP transgenic mice. Nat Commun. 2013;4:1939.
   PubMed Web of Science ®Google Scholar
• Di L. Strategic approaches to optimizing peptide ADME properties. Aaps J. 2015;17:134–143.
   PubMed Web of Science ®Google Scholar
• Gao S, Hu M. Bioavailability challenges associated with development of anti-cancer phenolics. Mini Rev Med Chem. 2010;10:550–567.
   PubMed Web of Science ®Google Scholar
• Zheng X, Wu C, Liu D, et al. Mechanism of C-terminal fragments of amyloid beta-protein as abeta inhibitors: do C-terminal interactions play a key role in their inhibitory activity?. J Phys Chem B. 2016; 120: 1615-23.
   Web of Science ®Google Scholar
• Offen D, Aharony I Peptides for the treatment of neurodegenerative diseases. EP2906583 A1. 2014.
   Google Scholar
• Saudou F, Humbert S. The biology of huntingtin. Neuron. 2016;89:910–926.
   PubMed Web of Science ®Google Scholar
• Tallaksen-Greene SJ, Crouse AB, Hunter JM, et al. Neuronal intranuclear inclusions and neuropil aggregates in HdhCAG(150) knockin mice. Neuroscience. 2005;131:843–852.
   PubMed Web of Science ®Google Scholar
• Gafni J, Papanikolaou T, Degiacomo F, et al. Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. J Neuroscience: Official Journal Soc Neurosci. 2012;32:7454–7465.
   PubMed Web of Science ®Google Scholar
• Graham RK, Deng Y, Carroll J, et al. Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. J Neuroscience: Official Journal Soc Neurosci. 2010;30:15019–15029.
   PubMed Web of Science ®Google Scholar
• Wellington CL, Singaraja R, Ellerby L, et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem. 2000;275:19831–19838.
   PubMed Web of Science ®Google Scholar
• Halawani D, Tessier S, Anzellotti D, et al. Identification of Caspase-6-mediated processing of the valosin containing protein (p97) in Alzheimer’s disease: a novel link to dysfunction in ubiquitin proteasome system-mediated protein degradation. J Neuroscience: Official Journal Soc Neurosci. 2010;30:6132–6142.
   PubMed Web of Science ®Google Scholar
• Kaplan A, Stockwell BR. Therapeutic approaches to preventing cell death in Huntington disease. Prog Neurobiol. 2012;99:262–280.
   PubMed Web of Science ®Google Scholar
• LeBlanc AC. Caspase-6 as a novel early target in the treatment of Alzheimer’s disease. Eur J Neurosci. 2013;37:2005–2018.
   PubMed Web of Science ®Google Scholar
• Anagli J, Seyfried D Methods, systems, and compositions for calpain inhibition. US9074019 B2. 2015.
   Google Scholar
• Nelson A Use of cyclodextrins for the treatment of cerebral ischaemia and central nervous system injury WO2000004888A2. 2000.
   Google Scholar
• Ellerby LM, Ellman JA, Leyva MJ Caspase inhibitors and uses thereof. US20140011847 A1. 2014.
   Google Scholar
• Goffredo D, Rigamonti D, Zuccato C, et al. Prevention of cytosolic IAPs degradation: a potential pharmacological target in Huntington’s disease. Pharmacological Res. 2005;52:140–150.
   PubMed Web of Science ®Google Scholar
• Xu F, Sun C, Wang J Uses of 2-[(4-formyl-pyrazol-5-yl)-thio]acetic acid derivatives in preparation of Caspase-3 inhibitors. CN104138372 A. 2013.
   Google Scholar
• Galvan V, Chen S, Lu D, et al. Caspase cleavage of members of the amyloid precursor family of proteins. J Neurochem. 2002;82:283–294.
   PubMed Web of Science ®Google Scholar
• Fan W, Qiao ZB, Zhu XM, et al. Application of caspase-3 inhibitor to prepare for promoting nerve regeneration after cerebral stroke. CN201310371351. 2013.
   Google Scholar
• Fan W, Dai Y, Xu H, et al. Caspase-3 modulates regenerative response after stroke. Stem Cells. 2014;32:473–486.
   PubMed Web of Science ®Google Scholar
• Rosell A, Cuadrado E, Alvarez-Sabin J, et al. Caspase-3 is related to infarct growth after human ischemic stroke. Neurosci Lett. 2008;430:1–6.
   PubMed Web of Science ®Google Scholar
• Sun Y, Xu Y, Geng L. Caspase-3 inhibitor prevents the apoptosis of brain tissue in rats with acute cerebral infarction. Exp Ther Med. 2015;10:133–138.
   PubMed Web of Science ®Google Scholar
• Watanabe C, Shu GL, Zheng TS, et al. Caspase 6 regulates B cell activation and differentiation into plasma cells. J Immunol. 1950;2008(181):6810–6819.
   Google Scholar
• Estaquier J Caspase-6 inhibitors for treating t cell activation and/or proliferation disorders. WO2014060392 A1. 2014.
   Google Scholar
• Gregoli PA, Bondurant MC. Function of caspases in regulating apoptosis caused by erythropoietin deprivation in erythroid progenitors. J Cell Physiol. 1999;178:133–143.
   PubMed Web of Science ®Google Scholar
• Brown TL. Q-VD-OPh, ne`xt generation caspase inhibitor. Adv Exp Med Biol. 2004;559:293–300.
   PubMed Web of Science ®Google Scholar
• Ahlfors J, Mekouar K Selective caspase inhibitors and uses thereof. US9045524 B2. 2015.
   Google Scholar
• Shabanzadeh AP, D’Onofrio PM, Monnier PP, et al. Targeting caspase-6 and caspase-8 to promote neuronal survival following ischemic stroke. Cell Death Dis. 2015;6:e1967.
   PubMed Web of Science ®Google Scholar
• Tang J, An XL, Song HG, et al. [The changes of histology and biochemical parameters in retina of the patient with diabetic retinopathy]. Zhonghua Yan Ke Za Zhi. 2004;40:689–691.
   PubMedGoogle Scholar
• Prescimone T, D’Amico A, Caselli C, et al. Caspase-1 transcripts in failing human heart after mechanical unloading. Cardiovasc Pathol. 2015;24:11–18.
   PubMed Web of Science ®Google Scholar
• Ilzecka J. Serum caspase-9 levels are increased in patients with amyotrophic lateral sclerosis. Neurol Sci. 2012;33:825–829.
   PubMed Web of Science ®Google Scholar
• King AJ, Arnone MR, Bleam MR, et al. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS One. 2013;8:e67583.
   PubMed Web of Science ®Google Scholar
• Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012;11:909–920
   PubMed Web of Science ®Google Scholar
• Miao ZH, Li JX, Feng JM Application of dabrafenib for programmed necrosis inhibition and liver protection. CN103520162 B. 2013.
   Google Scholar
• Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379:1893–1901.
   PubMed Web of Science ®Google Scholar
• Hong DS, Vence L, Falchook G, et al. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res. 2012;18:2326–2335.
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444–451.
   PubMed Web of Science ®Google Scholar
• Zack DJ, Welsbie DS, Yang Z Compounds and methods of use thereof for treating neurodegenerative disorders. WO2013177367 A2. 2013.
   Google Scholar
• Tomita H, Nakazawa T, Sugano E, et al. Nipradilol inhibits apoptosis by preventing the activation of caspase-3 via S-nitrosylation and the cGMP-dependent pathway. Eur J Pharmacol. 2002;452:263–268.
   PubMed Web of Science ®Google Scholar
• Chi W, Li F, Chen H, et al. Caspase-8 promotes NLRP1/NLRP3 inflammasome activation and IL-1beta production in acute glaucoma. Proc Natl Acad Sci U S A. 2014;111:11181–11186.
   PubMed Web of Science ®Google Scholar
• Bannen L c-Met modulators and methods of use US20070054928 A1. 2007.
   Google Scholar
• Xiang Q, Zhen Z, Deng DY, et al. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015;34:118.
   PubMed Web of Science ®Google Scholar
• Katayama R, Kobayashi Y, Friboulet L, et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res. 2015;21:166–174.
   PubMed Web of Science ®Google Scholar
• Katayama R, Sakashita T, Yanagitani N, et al. P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. EBioMedicine. 2016;3:54–66.
   PubMed Web of Science ®Google Scholar
• Janne PA, Meyerson M. ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma. J Clin Oncol. 2012;30:878–879.
   PubMed Web of Science ®Google Scholar
• Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863–870.
   PubMed Web of Science ®Google Scholar
• Zillhardt M, Park SM, Romero IL, et al. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res. 2011;17:4042–4051.
   PubMed Web of Science ®Google Scholar
• Shah MA, Wainberg ZA, Catenacci DV, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. Plos One. 2013;8:e54014.
   PubMed Web of Science ®Google Scholar
• Qian F, Engst S, Yamaguchi K, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 2009;69:8009–8016.
   PubMed Web of Science ®Google Scholar
• Cheng JW, Cheng SW, Wei R, et al. Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery. Cochrane Database Syst Rev. 2016;15(1):Cd009782.
   Google Scholar